NCT06898034 Postpartum Ultrasound Evaluation to Assess Risk of Hemorrhage
| NCT ID | NCT06898034 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Endeavor Health |
| Condition | Pregnancy Related |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,725 participants |
| Start Date | 2025-03-10 |
| Primary Completion | 2027-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,725 participants in total. It began in 2025-03-10 with a primary completion date of 2027-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Up to 5% of patients in the United States have a postpartum hemorrhage. "Postpartum hemorrhage" means excessive bleeding after delivery. The majority of these bleeds occur immediately with delivery. The current study focuses on hemorrhages that occur in the "medium-term" (1.5-24 hours after delivery). Investigators are examining whether ultrasound exams performed at the beginning of this period 1.5 to 2 hours after birth can identify markers that predict a medium-term bleed. Data collected for this study will include medical and obstetrical history, details about the course and outcomes of patients' labor and delivery, and particulars about postpartum bleeding. This information will be collected through the end of the patients' delivery admission and will allow correlation with the results of the ultrasound exam. If patients are re-admitted to the hospital after the delivery discharge, investigators may also collect relevant information about those admissions up to 6 weeks postpartum. All patients after term delivery (≥ 37 weeks' gestation) will be eligible to participate. Patients will be approached to provide consent for participation as early as feasible during a prenatal visit (≥ 36 weeks' gestation) or during the delivery admission. No subjects will be consented while in significant pain, \>6cm dilated without an epidural, or \>8cm dilatated with an epidural.
Eligibility Criteria
Inclusion Criteria: * Currently pregnant and planning to deliver at Endeavor Health \>37 weeks gestational age * English speaking * Labor \<6cm dilated at time of consent without epidural * Labor \<8cm dilated at time of consent with epidural Exclusion Criteria: * Preterm delivery * Non-English speaking * Any conditions that impairs potential participants decision making
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06898034 clinical trial?
This trial is open to female participants only, aged 17 Years or older, studying Pregnancy Related. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06898034 currently recruiting?
Yes, NCT06898034 is actively recruiting participants. Contact the research team at KHoneyfield@northshore.org for enrollment information.
Where is the NCT06898034 trial being conducted?
This trial is being conducted at Evanston, United States.
Who is sponsoring the NCT06898034 clinical trial?
NCT06898034 is sponsored by Endeavor Health. The trial plans to enroll 1,725 participants.